LianBio announced that Yizhe Wang, CEO has resigned from LianBio to pursue other opportunities. In connection with his departure, the LianBio board of directors has appointed Adam Stone, chief investment officer of perceptive advisors and member of the LianBio board of directors as interim CEO. LianBio’s board of directors will continue to represent the best interests of LianBio and its shareholders and evaluate strategic alternatives for the company. The board of directors expects to communicate an update on the ongoing strategic review in the first quarter of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LIAN:
- LianBio Announces Departure of Chief Executive Officer
- LianBio board determines not to pursue Concentra Biosciences proposal
- LianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences
- LianBio confirms receipt of unsolicited proposal from Concentra Biosciences
- LianBio price target lowered to $5 from $6 at BofA
